Leukemia and Lymphoma Clinical Trials

Full title:

AALL2121, A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-R infant leukemia

Study goal:

To find the best dose of SNDX-5613 to use along with chemotherapy for young patients with KMT2A-R leukemia

Diagnosis:

Acute lymphoblastic leukemia (ALL); acute leukemia of ambiguous lineage (ALAL); mixed phenotype acute leukemia (MPAL); or acute myeloid leukemia (AML) that was previously ALL, ALAL, or MPAL with a KMT2A gene rearrangement 

Age:

1 month to 5 years old

Full title:

A Collaborative Phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia

Study goal:

Study the side effects of using venetoclax and chemotherapy to treat children with AML; learn more about how this treatment works

Diagnosis:

Acute myeloid leukemia (AML)

Age:

Older than 28 days and younger than 22 years

Full title:

A Randomized Phase 3 Trial of Fludarabine/ Cytarabine/ Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Study goal:

To find out if adding venetoclax to standard chemotherapy leads to improved survival for children and young adults with relapsed AML.

Diagnosis:

Acute myeloid leukemia

Age:

29 days old to 21 years old

Full title:

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Study goal:

The main purpose of this study is to find the highest dose of CD123-CAR T cells that is safe to give patients with AML.  We also want to study the side effects of the treatment and learn how effective it is in fighting this type of cancer.

Diagnosis:

Acute Myeloid Leukemia

Age:

21 years old or younger

Full title:

A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms 

Study goal:

This study will help us understand the effects of CPX-351 treatment in patients with MDS and AML.

Diagnosis:

Acute myeloid leukemia, myelodysplastic syndromes

Age:

1-22 years old

Full title:

CAR T–Cell Therapy Directed to CD70 for Pediatric Patients with Hematological Malignancies (DIRECT70)

Study goal:

The purpose of this study is to find the highest dose of CD70+ CAR cells that is safe to give to patients with CD70+ blood cancers.

Diagnosis:

ALL, AML, MDS, Lymphoma

Age:

Up to 21 years old

Study goal:

The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.

Diagnosis:

Leukemia, lymphoma, genetics and genomics, solid tumor

Full title:

Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

Study goal:

Understand the relationship among cardiopulmonary function, carotid sinus baroreceptors and CO2 sensing organs, and cerebral blood flow regulation in Hodgkin lymphoma survivors

Diagnosis:

Hodgkin lymphoma

Age:

Age 18 and up

Full title:

Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia

Study goal:

The main goal of this study is to learn about the good and bad side effects of inotuzumab ozogamicin in children with this type of leukemia and to find out how well the drug works to get rid of the disease.

Diagnosis:

Acute lymphoblastic leukemia

Age:

Younger than 22 years old

Full title:

A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia

Study goal:

The main goal of this study is to learn the largest dose of memory CAR T cells that can be safely given. Researchers also want to learn about the way memory CAR T cells act in the body and how effectively they treat this type of cancer.

Diagnosis:

Acute lymphoblastic leukemia

Age:

Donor: At least 19 years old; Recipient: 21 years or younger

Full title:

Mobile Technology to Improve Pain and Symptoms in Children With Cancer

Study goal:

The main goal of this research study is to help us learn how to better treat pain and symptoms in children going through chemotherapy cancer treatment.

Diagnosis:

ALL, AML, carcinoma, endocrine tumors, lymphoma, melanoma, neuroblastoma, retinoblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, sarcomas

Age:

8 to 18 years old

Full title:

PARPAML: A Phase 1 Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy

Study goal:

To study the effects of talazoparib and chemotherapy for treating relapsed or refractory acute myeloid leukemia and acute myeloid leukemia of ambiguous lineage and to find the best dose for children and young adults.

Diagnosis:

Acute myeloid leukemia, acute leukemia of ambiguous lineage

Age:

Up to age 21

Full title:

A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Study goal:

The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.

Diagnosis:

Solid tumors, Non-Hodgkin lymphoma, Desmoid tumors, Ewing sarcoma, Osteosarcoma, Hepatocellular carcinoma, Hepatoblastoma, Wilms tumor

Age:

12 months to 30 years

Full title:

A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

Study goal:

The main purpose of this study is to find the highest, safest dose of CBL0137 that can be given to children, teens and young adults with solid tumors or lymphoma.

Diagnosis:

Solid Tumor, Lymphoma, Brain Tumor, DMG

Age:

12 months to 21 years old with diagnosis of relapsed or refractory solid tumor or lymphoma (including CNS tumors) or progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy; 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Full title:

A Phase 1 Study of GRN163L (Imetelstat) in Combination with Fludarabine and Cytarabine for Patients with Acute Myeloid Leukemia that is in Second or Greater Relapse or that is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

Study goal:

To find the safest dose of imetelstat that can be given with fludarabine and cytarabine to stop the growth of cancer cells.  

Diagnosis:

Acute myeloid leukemia, myelodysplastic syndromes, juvenile myelomonocytic leukemia

Age:

Between 12 months and 18 years old

Full title:

A Phase 1 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia

Study goal:

Find out the dose of revumenib, azacitidine and venetoclax that can be used to safely treat children, adolescents, and young adults with refractory or relapsed AML or ALAL

Diagnosis:

Acute myeloid leukemia or acute leukemia of ambiguous lineage

Age:

1–30 years old

Full title:

A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Study goal:

The main goals of this study are to test the safety of venetoclax and selinexor and find the highest dose that is safe to give when combined with chemotherapy drugs. Researchers also want to find out about any side effects and learn how the treatment affects your body.

Diagnosis:

Acute myeloid leukemia

Age:

30 years or younger

Full title:

SJLIFE: Establishment of a Lifetime Cohort of Adults Surviving Childhood Cancer

Study goal:

To establish a lifetime group of childhood cancer survivors treated at St. Jude Children’s Research Hospital and to evaluate health outcomes in aging survivors of pediatric cancer

Age:

Participants must be at least 5 years from diagnosis of childhood cancer between 1962-2012, treated and followed at St. Jude

Full title:

SJLTFU: Protocol for Collecting Data on Childhood Cancer Survivors

Study goal:

To collect information about the effects of childhood cancer and its treatment on the patients who are treated or followed after treatment for childhood cancer at St. Jude Children’s Research Hospital

Full title:

TRIALS: Transfusional Iron Overload Among Leukemia Survivors

Study goal:

1) To find out how many long-term survivors of leukemia have iron overload by using MRI testing. 2) To study how the number of red blood cell transfusions you received determines whether you have iron overload. 3) To explore how your age at the time of cancer therapy, the length of time from therapy, and gender affects whether you develop iron overload. 4) To find out if iron overload is causing problems with your organs.

Diagnosis:

Leukemia Survivors

Full title:

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Study goal:

The main goal of this study is to see if this approach can reduce treatment-related late effects in children and young adults with Hodgkin lymphoma.

Diagnosis:

Hodgkin Lymphoma

Age:

21 years or younger (low-risk patients)